The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027
Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography
Systemic Lupus Erythematosus – our new study reveals trends, R&D progress, and predicted revenues Where is the SLE market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover How to Stay Ahead Our 152-page report provides 114 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing SLE market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, there are forecasts for 7 Products, 3 Molecule Types and 4 Pharmacological Classes
Systemic Lupus Erythematosus Market Forecasts to 2027, By Molecule Type • Small Molecules • Monoclonal Antibodies • Recombinant Proteins
Systemic Lupus Erythematosus Market Forecasts to 2027, By Pharmacological Class • B-Cell Targeting Therapies • Interferon Receptor Antagonists • CD Antagonist Therapies • Other Therapies for SLE
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 2 regional and 9 leading national markets: • Regional Markets: • LATAM (including Brazil) • Asia Pacific
• National Markets: • The US • Canada • Germany • France • The UK • Italy • Spain • Japan • China
The report also includes profiles and forecasts for some of the leading companies in the Systemic Lupus Erythematosus market, with a focus on the SLE segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the developing markets, China in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market.
Leading companies and the potential for market growth Overall world revenue for SLE will surpass $570m in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing prevalence of autoimmune disease, and increasing ageing population will increase sales to 2027.
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the SLE Market report helps you In summary, our 152-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the world Systemic Lupus Erythematosus market and 3 different segmentations, with forecasts for 7 Products, 3 Molecule Types and 4 Pharmacological Classes – discover the industry’s prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 2 regional markets and 9 of the leading national markets – LATAM (Including Brazil), APAC, US, Canada, Germany, UK, France, Italy, Spain, Japan, China, • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the Systemic Lupus Erythematosus market and leading companies. You will find data, trends and predictions.
Get our report today The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography. Avoid missing out – get our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Systemic Lupus Erythematosus (SLE) Market Definition 1.2 Methodology 1.2.1 Primary Research 1.2.2 Secondary Research 1.2.3 Market Evaluation & Forecasting Methodology 1.3 Systemic Lupus Erythematosus (SLE) Report Structure 1.4 Why You Should Read This Report 1.5 How this Report Delivers 1.6 Key Questions Answered by This Analytical Report Include: 1.7 Who is This Report For? 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2. Introduction to Systemic Lupus Erythematosus 2.1 Aetiology 2.2 Pathophysiology 2.3 Constitutional 2.4 Prognosis 2.5 Symptoms 2.6 Diagnosis 2.7 Assessing the Health Status of SLE patients 2.8 Current Treatment Options 2.9 Unmet Needs
3. Epidemiology 3.1 Prevalence 3.2 Incidence Rates (New Cases/Year) 3.3 Mortality 3.4 Hospitalizations 3.5 Ambulatory Care 3.6 Costs 3.7 Impact on Health-Related Quality of Life (HRQOL)
4. Systemic Lupus Erythematosus Market Forecast 2017-2027 4.1 Total population in US, EU, Japan and China 4.2 Systemic Lupus Erythematosus Prevalence Rate in US, EU, Japan and China 4.3 Diagnosed Systemic Lupus Erythematosus Population in US, EU, Japan and China 4.4 Systemic Lupus Erythematosus Drug Treated Patients in US, EU, Japan and China 4.5 Pricing Trends of the Market 4.6 Atacicept Sales Forecast 2017-2027 4.7 Benlysta Sales Forecast 2017-2027 4.8 Anifrolumab Sales Forecast 2017-2027 4.9 Lulizumab Sales Forecast 2017-2027 4.10 Bisibimod Sales Forecast 2017-2027 4.11 CellCept Sales Forecast 2017-2027 4.12 Prograf Sales Forecast 2017-2027 4.13 All Key SLE Therapies Sales
6. SLE Market Forecast By Molecule Type 2017-2027 6.1 Small Molecules Sales Forecast 2017-2027 6.2 Monoclonal Antibodies Sales Forecast 2017-2027 6.3 Recombinant Proteins Sales Forecast 2017-2027 6.4 Comparative Sales Analysis 6.5 Market Share – By Molecule Type
7. SLE Market Forecast by Pharmacological Class 2017-2027 7.1 B-Cell Targeting Therapies Sales Forecast 2017-2027 7.2 Interferon Receptor Antagonist Sales Forecast 2017-2027 7.3 CD Antagonist Therapies Sales Forecast 2017-2027 7.4 Other Therapies for SLE 7.5 Market Share – By Pharmacological Class Sales 7.6 Market Share – By Pharmacological Class Sales 7.7 Comparative analysis – Sales by Pharmacological Class Sales
8. Leading National Markets in the Systemic Lupus Erythematosus Market 8.1 US SLE Sales Forecast 2017-2027 8.2 Japan SLE Sales Forecast 2017-2027 8.3 China SLE Sales Forecast 2017-2027 8.4 LATAM (Including Brazil) SLE Sales Forecast 2017-2027 8.5 UK SLE Sales Forecast 2017-2027 8.6 France SLE Sales Forecast 2017-2027 8.7 Germany SLE Sales Forecast 2017-2027 8.8 Italy SLE Sales Forecast 2017-2027 8.9 Spain SLE Sales Forecast 2017-2027 8.10 Canada SLE Sales Forecast 2017-2027 8.11 APAC SLE Sales Forecast 2017-2027 8.12 Comparative analysis – EU Sales 8.13 Market Share – By EU Countries Sales 8.14 Market Share – By EU Countries Sales 8.15 Comparative analysis – US and EU Sales 8.16 Comparative analysis – China and Japan Sales 8.17 Comparative analysis – APAC and LATAM Sales 8.18 Comparative analysis – Key Market Sales
9. Product Launch timelines 9.1 Timeline of USA Launches 9.2 Timeline of EU Launches 9.3 Timeline of Japan Launches
10. Company Profiles 10.1 Anthera Company Profile 10.1.1 Anthera Company Overview 10.1.2 Anthera Projects Overview 10.1.3 Anthera Recent Deals 10.2 GSK Company Profile 10.2.1 GSK Company Overview 10.2.2 GSK Projects Overview 10.2.3 GSK Recent Deals 10.3 ImmuPharma Company Profile 10.3.1 ImmuPharma Company Overview 10.3.2 ImmuPharma Projects Overview 10.3.3 ImmuPharma Recent Deals 10.4 Merck Company Profile 10.4.1 Merck KGaA Company Overview 10.4.2 Merck Projects Overview 10.4.3 Merck Recent Deals 10.5 AstraZeneca Company Profile 10.5.1 AstraZeneca Company Overview 10.5.2 AstraZeneca Projects Overview 10.5.3 AstraZeneca Recent Deals 10.6 Eli Lilly Company Profile 10.6.1 Eli Lilly Company Overview 10.6.2 Eli Lilly Projects Overview 10.6.3 Eli Lilly Recent Deals 10.7 Other SLE companies
11. Qualitative Analysis of the Systemic Lupus Erythematosus Market 11.1 Strengths of the Systemic Lupus Erythematosus Market 11.2 Weakness of the Systemic Lupus Erythematosus Market 11.3 Opportunities for the Systemic Lupus Erythematosus Market 11.4 Threats for the Systemic Lupus Erythematosus Market 11.5 Political Factors Influencing the Systemic Lupus Erythematosus Market 11.6 Economical Factors Influencing the Systemic Lupus Erythematosus Market 11.7 Social Factors Influencing the Systemic Lupus Erythematosus Market 11.8 Technological Factors influencing the Systemic Lupus Erythematosus market
12. Key Findings and Report Conclusion 12.1 Cost of Therapies in Systemic Lupus Erythematosus 12.2 Geographical Trends of Systemic Lupus Erythematosus Market 12.3 Future of the Systemic Lupus Erythematosus Market
13. Glossary Associated Visiongain Reports Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Figures Figure 4.1 Atacicept Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 4.2 Benlysta Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 4.3 Anifrolumab Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 4.4 Lulizumab Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 4.5 Bisibimod Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 4.6 CellCept Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 4.7 Prograf Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 4.8 All Key SLE Therapies Sales 2017-2027 Figure 6.1 Small Molecules Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 6.2 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 6.3 Recombinant Proteins Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 6.4 Comparative analysis Sales 2017-2027 Figure 6.5 Market Share – By Molecule Type Sales 2022 Figure 6.6 Market Share – By Molecule Type Sales 2027 Figure 7.1 B- Cell Targeting Therapies Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 7.2 Interferon Receptor Antagonist Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 7.3 CD Antagonist Therapies Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 7.4 Other Therapies in SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 7.5 Market Share – By Pharmacological Class Sales 2022 Figure 7.6 Market Share – By Pharmacological Class Sales 2027 Figure 7.7 Comparative analysis – Sales by Pharmacological Class Sales 2017-2027 Figure 8.1 US SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.2 Japan SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.3 China SLE Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.4 LATAM (Including Brazil) SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.5 UK SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.6 France SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.7 Germany SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.8 Italy SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.9 Spain SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.10 Canada SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.11 APAC SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027 Figure 8.12 Comparative analysis – EU-5 Sales 2017-2027 Figure 8.13 Market Share – By EU-5 Countries Sales 2022 Figure 8.14 Market Share – By EU-5 Countries Sales 2027 Figure 8.15 Comparative analysis – US and EU-5 Sales 2017-2027 Figure 8.16 Comparative analysis – China and Japan Sales 2017-2027 Figure 8.17 Comparative analysis – APAC and LATAM Sales 2017-2027 Figure 8.18 Comparative analysis – Key Market Sales 2017-2027 Figure 10.1 Anthera project overview by development stage Figure 10.2 Anthera project overview by Therapeutic area Figure 10.3 GSK project overview by development stage Figure 10.4 GSK project overview by Therapeutic area Figure 10.5 ImmuPharma project overview by development stage Figure 10.6 Immupharma project overview by Therapeutic area Figure 10.7 Merck project overview by development stage Figure 10.8 Merck project overview by Therapeutic area Figure 10.9 AstraZeneca project overview by development stage Figure 10.10 AstraZeneca project overview by Therapeutic area Figure 10.11 Eli Lilly project overview by development stage Figure 10.12 Eli Lilly project overview by Therapeutic area
3SBio AbbVie Ablynx Actelion Active Biotech Alkermes Allergan AMEGA Biotech Amgen AstraZeneca Aurinia Pharmaceuticals Beijing SL Pharmaceutical Biogen BioSense Global Biotest Boehringer Ingelheim Bristol-Myers Squibb Celgene Chong Kun Dang CipherPharmaceuticals CSL Eli Lilly GSK Helion Biotech Idera Pharmaceuticals ILTOO Pharma Immungenetics Immunomedics ImmuPharma Incyte Innovent Biologics Intrexon Invion Ionis Pharmaceuticals Japan Tobacco Johnson & Johnson Kadmon Ligand Pharmaceuticals MacroGenics Medsenic Merck Mitsubishi Tanabe Pharma Nano Terra Nektar Therapeutics Neovacs Omeros Ono Pharmaceutical PDL BioPharma Pfizer Resolve Therapeutics Roche Sanofi Seattle Genetics Shenzhen Beike Biotechnology Shire Takeda Teva TheraMAB UCB Weizmann Institute of Science Xencor XTL Biopharmaceuticals
List of Organizations Aarhus University Charité Universitätsmedizin Berlin Development Center for Biotechnology Food and Drug Administration (FDA) Ministry of Health, Labor, and Welfare (MHLW) National Health Service (UK) National Institutes of Health (NIH) University of Leicester University of Miami University of Washington World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027
Download sample pages
Complete the form below to download your free sample pages for The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
The global Stem Cell Therapy Contract Manufacturing market was valued at US$2,495.1 million in 2022 and is projected to grow at a CAGR of 12.4% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
